Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

National Medical Care

This article was originally published in The Gray Sheet

Executive Summary

Parent W. R. Grace says the firm "is cooperating with FDA and has instituted a comprehensive program to address...concerns" that led the agency to impose an import ban on hemodialysis bloodlines produced at NMC's Reynosa, Mexico facility and hemodialyzers manufactured at its Dublin, Ireland plant. Grace announced on Aug. 5 that the FDA enforcement action "will not affect full year earnings growth from Grace's health care business".

Latest Headlines
See All
UsernamePublicRestriction

Register

MT001021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel